Clinical Chemistry
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 43: 649-656, 1997;
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Web of Science (17)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kreutz, F. T.
Right arrow Articles by Suresh, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kreutz, F. T.
Right arrow Articles by Suresh, M. R.
Related Collections
Right arrow Clinical Immunology
Right arrow Proteomics and Protein Markers
Right arrow Automation and Analytical Techniques
(Clinical Chemistry. 1997;43:649-656.)
© 1997 American Association for Clinical Chemistry, Inc.

Articles

Novel bispecific immunoprobe for rapid and sensitive detection of prostate-specific antigen

Fernando T. Kreutz and Mavanur R. Suresha

a Author for correspondence. Fax 403-492-8241; e-mail msuresh{at}gpu.srv.ualberta.ca

Prostate-specific antigen (PSA) is one of the most useful tumor markers for the screening and follow-up of prostate cancer. Bispecific monoclonal antibodies (bsMAbs) are unique immunoprobes that incorporate two different binding sites in the same antibody molecule. This antibody designing can bring important advantages in the development of new immunoassays. We have developed a new hybrid hybridoma that secretes bsMAb anti-PSA x anti-horseradish peroxidase. This bsMAb has shown rapid kinetics and an excellent detection limit in a sandwich single-step assay with a total incubation time of 15 min and a 5-min substrate development. This assay in a manual format has a detection limit of 0.028 µg/L. Comparison with the Hybritech Tandem-E® PSA assay yielded a regression equation with slope = 0.433 [95% confidence interval (CI) = 0.415–0.451], intercept = 0.88 (CI = 0.45–1.31), and Sy|x = 1.83 µg/L (r = 0.98). This new immunoprobe can be used to develop a new generation of assays for clinical laboratories and can be adapted to screening devices for physicians' offices and even home diagnostics.


Key Words: indexing terms: bispecific antibodies • tumor markers • screening • hybrid hybridoma • quadroma






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American Association for Clinical Chemistry.